A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Latest Information Update: 05 Jan 2024
At a glance
- Drugs Nipocalimab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms Vivacity-MG
- Sponsors Momenta Pharmaceuticals
- 23 Jan 2024 Results assessing safety and efficacy of Nipocalimab(n=68) , published in the Neurology journal.
- 16 Oct 2023 According to Janssen media release, data from this study will be presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Meeting
- 26 Apr 2022 Results from NCT02828046, NCT03772587 evaluating effect of nipocalimab on immune function, presented at the 74th Annual Meeting of the American Academy of Neurology 2022